What is William Blair’s Forecast for ZVRA FY2024 Earnings?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Analysts at William Blair dropped their FY2024 earnings per share estimates for Zevra Therapeutics in a research note issued to investors on Wednesday, November 13th. William Blair analyst S. Corwin now anticipates that the company will post earnings of ($2.00) per share for the year, down from their previous estimate of ($1.58). William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.92) per share. William Blair also issued estimates for Zevra Therapeutics’ Q4 2024 earnings at ($0.42) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.70) EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). The firm had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same quarter in the prior year, the company posted ($0.40) earnings per share.

Other equities research analysts have also recently issued reports about the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a research report on Friday, October 11th. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a report on Monday, September 30th. Maxim Group increased their target price on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Canaccord Genuity Group dropped their price target on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Guggenheim began coverage on Zevra Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $20.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Zevra Therapeutics has a consensus rating of “Buy” and a consensus price target of $21.00.

Zevra Therapeutics Stock Performance

Shares of ZVRA stock opened at $8.62 on Monday. The firm has a market capitalization of $453.58 million, a price-to-earnings ratio of -4.38 and a beta of 1.93. The stock has a fifty day moving average of $8.03 and a 200 day moving average of $6.50. Zevra Therapeutics has a 52 week low of $4.18 and a 52 week high of $9.21. The company has a quick ratio of 2.00, a current ratio of 2.88 and a debt-to-equity ratio of 0.84.

Institutional Investors Weigh In On Zevra Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Sanctuary Advisors LLC purchased a new stake in Zevra Therapeutics during the 2nd quarter valued at about $474,000. Jacobs Levy Equity Management Inc. raised its holdings in Zevra Therapeutics by 102.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock worth $201,000 after acquiring an additional 17,557 shares during the last quarter. Simplify Asset Management Inc. bought a new position in Zevra Therapeutics in the 3rd quarter valued at approximately $833,000. Price T Rowe Associates Inc. MD purchased a new stake in Zevra Therapeutics during the 1st quarter valued at $64,000. Finally, Vanguard Group Inc. increased its holdings in shares of Zevra Therapeutics by 3.6% in the 1st quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after purchasing an additional 58,866 shares in the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.